ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pregnancy"

  • Abstract Number: 2083 • ACR Convergence 2022

    A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy

    Massimo Radin1, Irene Cecchi2, Francesca Crisafulli3, Evandro Mendes Klumb4, Guilherme Ramires De Jesús4, Miguel Ángel Saavedra5, Geraldine Vanessa Reyes-Navarro6, Luca iaccarino7, Maddalena Larosa7, Gabriella Moroni8, Francesco Tamborini9, dario Roccatello1, Laura Andreoli3, Cecilia Beatrice Chighizola10 and Savino Sciascia2, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy, 3University of Brescia, Brescia, Italy, 4Instituto Fernandes Figueira, Rio De Janeiro, Brazil, 5Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, 6Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, 7University of Padova, Padova, Italy, 8Humanitas University, Rozzano, Italy, 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 10University of Milan, Milano, Italy

    Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity…
  • Abstract Number: 0374 • ACR Convergence 2022

    The BASDAI Index During Pregnancy

    Olga Krichevskaya, Tatiana Dubinina, Ekaterina Ilinih, Svetlana Glukhova, Anastasia Demina and Irina Andrianova, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

    Background/Purpose: During pregnancy, BASDAI may reflect not only the activity of ankylosing spondylitis (AS), but also back pain and fatigue, that are associated with the…
  • Abstract Number: 0960 • ACR Convergence 2022

    Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus

    Hiromi Shimada1, Risa Wakiya1, shusaku nakashima2, Mikiya Kato1, taichi miyagi3, Yusuke Ushio4, Koichi Sugihara5, Rina Mino6, mao mizusaki6, Kanako Chujo7, Tomohiro Kameda1 and Hiroaki Dobashi8, 1Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 3Kagawa University, Kidagun, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 5Kagawa University, Miki-cho, Kita-gun, Japan, 6Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 7Kagawa University, Miki, Kita District, Kagawa, Japan, 8Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

    Background/Purpose: Women with Systemic lupus erythematosus (SLE) have more difficulty in achieving a successful pregnancy than healthy women, because of higher risks for adverse pregnancy…
  • Abstract Number: 2107 • ACR Convergence 2022

    Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension

    azalfa Lateef1, stephanie Bray2, Dulaney Wilson2, Jim Oates2 and Diane Kamen2, 1MUSC, Columbia, SC, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Advances in medicine for women with systemic lupus erythematosus (SLE) have led to improved pregnancy outcomes, but pregnancies are still high-risk and disparities remain.…
  • Abstract Number: 0941 • ACR Convergence 2022

    Surveying Adolescents with Rheumatic Disease for At-Risk Behavior

    Kristina Ciaglia1, Chetna Godiwala2, Chan-hee Jo2, Tracey Wright3, Lynnette Walters2 and Lorien Nassi1, 1University of Texas Southwestern, Dallas, TX, 2Scottish Rite Hospital for Children, Dallas, TX, 3UT Southwestern, Plano, TX

    Background/Purpose: Adolescents with rheumatic disease are often prescribed teratogenic medications, however few rheumatologists screen patients for sexual activity and provide referrals or contraceptive education due…
  • Abstract Number: 0961 • ACR Convergence 2022

    The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series

    Francesca Crisafulli1, MARIA CHIARA GERARDI2, Maria Letizia Urban3, Margherita Zen4, Melissa Padovan5, Valentina Canti6, Emanuela Praino7, Cecilia Nalli1, Francesca Ruffilli5, Francesca Saccon8, Micaela Fredi9, Liala Moschetti1, Giacomo Emmi3, Luca Iaccarino4, Andrea Doria10, Leonardo Santo7, Franco Franceschini1, Laura Andreoli1 and Angela Tincani11, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia and Rheumatology Unit, ASST G.O.M. Niguarda, Milan, Milano, Italy, 3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 4Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy, 5Rheumatology Unit, Azienda Ospedaliero-Universitaria of Ferrara, Ferrara, Italy, 6Division of Immunology, IRCCS San Raffaele Institute, Milano, Italy, 7Rheumatology Unit, Presidio Ospedaliero ‘Mons. Dimiccoli’, Barletta, Italy, 8Unit of Rheumatology, Department of Medicine, University of Padova and Fondazione Villa Salus, Mestra, Venezia, Italy, 9Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Manerbio, Italy, 10Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani, 2, 35128 Padova, Italy., Padova, Italy, 11Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy

    Background/Purpose: Belimumab (BEL) is an anti-BLyS monoclonal antibody approved for SLE treatment. As few data about BEL use with regard to pregnancy are available, the…
  • Abstract Number: 2191 • ACR Convergence 2022

    Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea

    In Ah Choi1, Ji Hyoun Kim2, Sung Hae Chang3, Hyun Jung Kim4 and Hyeong Sik Ahn4, 1Chungbuk National University, Cheongju, Republic of Korea, 2Chungbuk National University Hospital, Cheongju, Republic of Korea, 3Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, 4Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
  • Abstract Number: 0945 • ACR Convergence 2022

    Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry

    John Bridges1, Jing Li2, Melissa Mannion3, Gabriela Schmajuk4 and Jasvinder singh3, 1University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 2University of California, San Francisco, San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4UCSF / SFVA, San Francisco, CA

    Background/Purpose: Patients with juvenile idiopathic arthritis (JIA) have disease onset during childhood and often require anti-rheumatic medication through their reproductive years. Contraception use in reproductive-age…
  • Abstract Number: 0962 • ACR Convergence 2022

    Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm

    Megan Clowse1, Jim Oates2, Katie Kirchoff2, April Barnado3, Saira Sheikh4, Leslie Crofford3 and Amanda Eudy5, 1Duke University, Durham, NC, 2Medical University of South Carolina, Charleston, SC, 3Vanderbilt University Medical Center, Nashville, TN, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Duke University, Raleigh, NC

    Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…
  • Abstract Number: 2192 • ACR Convergence 2022

    Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability

    Leah K. Flatman1, Yvan St. Pierre2, Isabelle Malhamé3, Olga Basso1, Anick Berard4, Sasha Bernatsky2 and Evelyne Vinet3, 1McGill University, Montréal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 3McGill University Health Centre, Montréal, QC, Canada, 4University of Montreal, Montréal, QC, Canada

    Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
  • Abstract Number: 0946 • ACR Convergence 2022

    The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE

    Catherine Sims1, Amanda Eudy2, Jayanth Doss1, Lisa Criscione-Schreiber3, Kai Sun3, Rebecca Sadun1, Jennifer L Rogers4 and Megan Clowse1, 1Duke University, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University School of Medicine, Durham, NC, 4Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC

    Background/Purpose: The ACR Reproductive Health Guidelines recommend that a woman conceive when her SLE is quiescent, she is not taking a teratogenic medication, and that…
  • Abstract Number: 0963 • ACR Convergence 2022

    Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy

    Antonia Chan1, Alanna Hirz1, Yashaar Chaichian1, Amadeia Rector2, Maurice Druzin3 and Julia Simard2, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Stanford University School of Medicine, Palo Alto

    Background/Purpose: Although hydroxychloroquine (HCQ) is strongly recommended in systemic lupus (SLE) pregnancy, the percentage of pregnant patients with SLE taking HCQ appears highly variable across…
  • Abstract Number: 0947 • ACR Convergence 2022

    Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases

    Mehret Birru Talabi1, Traci Kazmerski2, Raelynn O'Leary3, Ashley Deal3, Megan Clowse4, Oilvia Stransky5 and Sonya Borrero5, 1University of Pittsburgh, Pittsburgh, PA, 2Children's Hospital of Pittsburgh, Pittsburgh, 3Carnegie Mellon University School of Design, Pittsburgh, 4Duke University, Durham, NC, 5University of Pittsburgh, Pittsburgh

    Background/Purpose: Given the potential for pregnancy-associated mortality and morbidity, the question of whether and/or when to become pregnant is often a profoundly important decision for…
  • Abstract Number: 0964 • ACR Convergence 2022

    High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies

    Raeann Whitney, Sarah Green, Alex Camai, Ashley Suh, Katherine Walker, Wheless Lee and April Barnado, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Fetal growth restriction (FGR) and small for gestational age (SGA) are associated with increased perinatal morbidity and mortality. While Systemic lupus erythematosus (SLE) increases…
  • Abstract Number: 0948 • ACR Convergence 2022

    Fertility and the Use of Assisted Reproductive Technologies: Perceptions, Thoughts and Experiences of Men and Women with Rheumatic Disease

    Emily Peninger1, Molly Leavitt1, Cuoghi Edens1 and Shilpa Venkatachalam2, 1University of Chicago, Chicago, IL, 2Global Healthy Living Foundation, New York, NY

    Background/Purpose: Patients with rheumatic diseases have fewer biologic children than those without for a number of reasons, including infertility. Patients with rheumatic diseases may therefore…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology